Skip to Content

Brompheniramine / Codeine / Pseudoephedrine Dosage

Applies to the following strength(s): 2 mg-7.5 mg-30 mg/5 mL ; 1.33 mg-6.33 mg-10 mg/5 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Cough and Nasal Congestion

Brompheniramine/codeine/pseudoephedrine 1.33 mg-6.33 mg-10 mg/5 mL oral liquid:
15 mL orally every 4 to 6 hours not to exceed 90 mL daily

Brompheniramine/codeine/pseudoephedrine 2 mg-7.5 mg-30 mg/5 mL oral liquid:
10 mL orally every 4 to 6 hours not to exceed 6 doses daily

Comments:
-Liquid preparations should be measured with an accurate milliliter measuring device.

Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.

Usual Pediatric Dose for Cough and Nasal Congestion

Less than 12 years: Not Recommended

12 years or older:
-Brompheniramine/codeine/pseudoephedrine 1.33 mg-6.33 mg-10 mg/5 mL oral liquid:
15 mL orally every 4 to 6 hours not to exceed 90 mL daily

-Brompheniramine/codeine/pseudoephedrine 2 mg-7.5 mg-30 mg/5 mL oral liquid:
10 mL orally every 4 to 6 hours not to exceed 6 doses daily

-Liquid preparations should be measured with an accurate milliliter measuring device.
-Codeine should not be used in adolescents who are obese or have conditions such as sleep apnea or severe lung disease which may increase the risk of serious breathing problems.

Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.

Renal Dose Adjustments

Use with caution

Liver Dose Adjustments

Use with caution

Dose Adjustments

Elderly: Use with caution generally starting at the lower end of the dosing range

Precautions

The US FDA has issued a Drug Safety Communication restricting use of prescription codeine pain and cough medicines in children less than 12 years. This update follows previous communications evaluating the potential risks of codeine. Children less than 12 years appear to be at the greatest risk of codeine associated serious adverse events including slowed or difficult breathing and death. The FDA is considering additional regulatory action for over the counter (OTC) combination cough and cold products containing codeine. At this time, it appears prudent to avoid codeine use in all children less than 12 years and avoid use in adolescents between 12 and 18 years who are obese, or have conditions such as obstructive sleep apnea or severe lung disease, which may increase the risk of serious breathing problems.

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule V

Dialysis

Data not available

Other Comments

Administration advice:
-Take orally with or without food
-Oral measuring devices should be used to ensure accuracy in dosing; a household teaspoon should not be considered an accurate measuring device

Storage requirements:
-Protect from moisture and light

General:
-Patients who are ultra-rapid metabolizers of codeine due to a CYP450 2D6 polymorphism, will convert codeine more rapidly and completely to morphine resulting in unexpectedly high morphine levels, which may be life-threatening.
-Codeine use is contraindicated in the postoperative period in pediatric patients who have undergone tonsillectomy and/or adenoidectomy.

Monitoring:
-Cardiovascular: Monitor for signs of hypotension, especially in those whose blood pressure is compromised
-Respiratory: Monitor for respiratory depression
-Gastrointestinal: Monitor for constipation and decreased bowel motility
-Patients should be monitored for the development of addiction, abuse, or misuse.

Patient advice:
-Patients should understand that codeine use can result in addiction, abuse, and misuse.
-Patients should understand risks of life-threatening respiratory depression and when this risk is greatest; patients should be aware that a genetic mutation may result in greater codeine toxicity in some patients; breastfed infants of women who have this genetic mutation are also at risk.
-Women who are breastfeeding, pregnant, or planning to become pregnant should speak to their healthcare provider before using this product.
-This drug may cause drowsiness, dizziness, or impair thinking or motor skills; patients should avoid driving or operating machinery while taking this drug
-Concomitant use of alcohol, sedatives, and tranquilizers may increase drowsiness; patients should avoid alcohol and consult with their healthcare provider regarding concomitant use of other CNS depressants.

Hide